We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

By LabMedica International staff writers
Posted on 01 Dec 2023
Print article
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular disease. While not everyone who suffers from extreme stressors faces health complications later in life, a significant number do. For those affected, their cells tend to age more rapidly, leading to earlier physical breakdowns in the body, a phenomenon known as "accelerated biological aging." Natural aging processes typically involve a decline in cognitive functions, including memory, reasoning, executive function, and processing speed. Although global genetic research has generated mixed findings on whether accelerated biological aging kicks off early cognitive decline, previous studies suggest that early signs of cognitive decline can be identified long before they impact the quality of life. This opens up a window for early detection and intervention.

Now, a new study by researchers at Penn State (University Park, PA, USA) has unveiled genetic markers that could potentially forecast cognitive decline. According to the researchers, future blood tests might be able to detect early cell aging caused by these stressors, indicating a decline in cognitive abilities. In their study, the researchers analyzed two distinct population groups and found that accelerated biological aging might be a useful biomarker for identifying cognitive decline.

Utilizing blood samples and other medical data compiled from other studies, the researchers explored the relationship between potential genetic markers of cognitive performance, actual cognitive testing results, and the history of psychiatric disorders or childhood maltreatment. Their analysis revealed that accelerated biological aging is linked to reduced cognitive abilities and slower processing speed. However, the exact genetic markers indicating this relationship varied between the two study groups. The researchers attribute these differences to the distinct designs of the studies, suggesting that varying genetic markers could signal cognitive decline depending on the study's structure and focus.

“Understanding the connection between accelerated biological aging and cognitive decline may help researchers create treatments that help people who have experienced extreme stressors to experience better health,” said John Felt, assistant research professor in the Center for Healthy Aging and lead author of the study. “Cognitive decline can undermine your personal and professional life, especially for people who also have a psychiatric condition. Our research could lead to blood tests for early identification of cognitive decline and eventually to personalized treatments that support cognitive function in people with accelerated biological aging.”

Related Links:
Penn State 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.